Follow The Filings

WVE Wave Life Sciences

Wave Life Sciences earnings company data as of 4:47 AM ET 10/21

Limited consensus data for this ticker (thin coverage or data-plan limits). Dates may be company-announced rather than sell-side consensus. Calendar and recent prints remain the primary lens when available.

Scheduled

1 period, newest first, nothing reported yet. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 9 Nov EPS — — —
Rev — — —

Insider trades

Open-market buys and sales by WVE's executives, directors and 10% owners in the last 12 months, from their Form 4s

All WVE insider trades
  • $82.6M bought by 2 insiders
  • None no sales outside a trading plan
  • $15.9M sold by 8 insiders under 10b5-1 plans
  1. Heidi L Wagner Director
    Planned sale
    $42K 7,000 shares at $6.01 14% of stake
    Traded Aug 11 Filed Aug 13
    ↗
  2. Adrian Rawcliffe Director
    Planned sale
    $67K 12,700 shares at $5.29 100% of stake
    Traded Aug 12 Filed Aug 13
    ↗
  3. Ra Capital Management, L.P. Director, +3 joint filers
    Buy
    $54.6M 8,772,496 shares at $6.23 +48% to stake
    Traded Mar 26–30 Filed Mar 30
    ↗
  4. Chris Francis See Remarks
    Planned sale
    $500K 33,194 shares at $15.05 35% of stake
    Traded Feb 26 Filed Feb 27
    ↗
  5. Chris Francis See Remarks
    Planned sale
    $150K 9,375 shares at $16.03 27% of stake
    Traded Jan 2 Filed Jan 6
    ↗
  6. GSK plc 10% owner
    Buy
    $27.9M 1,470,000 shares at $19.00 +8.8% to stake
    Traded Dec 11, 2025 Filed Dec 15, 2025
    ↗
  7. Adrian Rawcliffe Director
    Planned sale
    $630K 42,000 shares at $15.00 77% of stake
    Traded Dec 8, 2025 Filed Dec 10, 2025
    ↗
  8. Heidi L Wagner Director
    Planned sale
    $189K 14,000 shares at $13.50 24% of stake
    Traded Dec 8, 2025 Filed Dec 10, 2025
    ↗
  9. Christian O Henry Director
    Planned sale
    $1.4M 93,445 shares at $14.65 88% of stake
    Traded Dec 8, 2025 Filed Dec 10, 2025
    ↗
  10. Aik Na Tan Director
    Planned sale
    $1.8M 134,218 shares at $13.58 84% of stake
    Traded Dec 8, 2025 Filed Dec 10, 2025
    ↗
  11. Gregory L. Verdine Director
    Planned sale
    $269K 20,000 shares at $13.47 6.8% of stake
    Traded Dec 8, 2025 Filed Dec 10, 2025
    ↗
  12. Chris Francis See Remarks
    Planned sale
    $6.4M 441,031 shares at $14.57 95% of stake
    Traded Dec 8, 2025 Filed Dec 10, 2025
    ↗
  13. Kyle Moran CFO
    Planned sale
    $4.1M 260,036 shares at $15.78 74% of stake
    Traded Dec 8–9 Filed Dec 10, 2025
    ↗
  14. Mark Corrigan Director
    Planned sale
    $217K 16,115 shares at $13.48 36% of stake
    Traded Dec 8, 2025 Filed Dec 10, 2025
    ↗
  15. Ra Capital Management, L.P. Director, +3 joint filers
    Buy
    $6,688 1,000 shares at $6.69 +<0.1% to stake
    Traded Nov 13, 2025 Filed Nov 14, 2025
    ↗

Also filed in the last 12 months, not counted as buying or selling: 28 option exercises, 12 stock grants, 6 sales to cover taxes, and 1 conversion.

SEC filings

Recent issuer filings from EDGAR, 22 shown.

Filed Form Detail Links
DEF 14A Filing Doc
SCHEDULE 13D/A — Filing Doc
8-K 2.02,7.01,9.01 Filing Doc
10-Q Filing Doc
8-K 5.07 Filing Doc
8-K 7.01,8.01,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
DEF 14A Filing Doc
SCHEDULE 13G/A — Filing Doc
10-K/A Filing Doc
8-K 2.02,7.01,9.01 Filing Doc
10-Q Filing Doc
8-K 8.01,9.01 Filing Doc
DEFA14A Filing Doc
SCHEDULE 13D/A — Filing Doc
8-K 1.01,8.01,9.01 Filing Doc
DEFA14A Filing Doc
SCHEDULE 13D/A — Filing Doc
8-K 7.01,8.01,9.01 Filing Doc
8-K 2.02,7.01,9.01 Filing Doc
10-K Filing Doc
SCHEDULE 13G/A — Filing Doc

Source: SEC EDGAR submissions, updated 5 days ago. All on EDGAR

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.